BCYC News and Press, Bicycle Therapeutics plc From 11/09/20

Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that preclinical data for BT7480, a tumor-targeted immune cell agoni...

Bicycle Therapeutics (BCYC): Q3 GAAP EPS of -$0.52 beats by $0.12.Revenue of $3.84M (+529.5% Y/Y) beats by $1.24M.Press Release For further details see: Bicycle Therapeutics EPS beats by $0.12, beats on revenue

- Three clinical trials of novel Bicycles ® initiated this quarter, including a Phase IIa for BT1718, a Phase I for BT8009, and a Phase II for THR-149 - Cash was $149.8 million at September 30, 2020, which includes net proceeds received during Q3 from completion o...

- Four renowned experts join to advise Bicycle as the company advances pipeline of novel cancer therapeutic candidates Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicy...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that preclinical data for BT7480, a tumor-targeted immune cell ...

Bicycle Therapeutics (BCYC) completed its at-the-market offering program initiated during Q3 generating gross proceeds of $50M.Also, it closed a financing with Hercules Capital (HTGC) for a term loan of up to $40M in two tranches; an initial tranche of $30M will be fully available a...

- ATM offering program initiated during Q3’20 fully utilized; $15.0 million drawn on debt financing facility of up to $40.0 million - Approximately $70 million generated during Q3’20 including ATM proceeds, debt financing draw and previously announced $6.7 millio...

VBL Therapeutics reports progress for metastatic colorectal cancer trial VBL Therapeutics ( VBLT ) announced the enrollment of the first two patients for its Phase 2 clinical trial of VB-111. The trial is designed to evaluate the potential of VB-111 used in combination with nivolumab for...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that a poster describing the design of the ongoing Phase I/II trial of BT8009 wi...

The first patient has been dosed in an open-label Phase 1/2 clinical trial evaluating Bicycle Therapeutics' (NASDAQ: BCYC ) BT8009, a Bicycle Toxin Conjugate (BTC) targeting a tumor antigen called nectin-4, in patients with advanced solid tumors. More news on: Bicycle Therapeutics plc,...